Dapsone therapy for the acute inflammatory phase of ocular pemphigoid

Alasdair I Fern, Jeffrey L Jay, Hamish Young, Rona MacKie

Abstract
Oral dapsone was used to treat five patients who presented in the acute inflammatory phase of ocular pemphigoid. The diagnosis was made clinically by identifying cicatrical changes which were in some cases difficult to find. In all cases it was the inflammatory rather than the cicatrical features which responded to treatment. An initial dose of 100 mg/day was effective without toxicity. When 150 mg/day was used patients experienced side effects. A clinical response was obtained after 1–4 weeks and could be maintained on a dose of between 50 mg on alternate days and 100 mg/day. Therapy was withdrawn during remissions which lasted up to 32 weeks but all cases required continuing therapy which has remained effective. Immunopathological examination was carried out on two occasions in all cases and although positive at least once the results did not correlate with disease activity or treatment. The inflammatory phase of ocular pemphigoid should be added to the list of diseases responsive to dapsone.

Cicatrical pemphigoid is a disease of unknown aetiology which results in chronic progressive blistering and scarring of mucosal epithelium. The oral mucosa is most commonly affected with the conjunctiva involved in 75% of cases and the skin in 21–30%. The eye changes are characterised by subepithelial fibrosis with symblepharon formation. There is also an acute inflammatory form of the disease with redness and swelling of the conjunctiva. In these cases of florid inflammation the cicatrical changes may be overlooked and the condition misdiagnosed.

Dapsone and other drugs of the sulfone group have been used for many years, particularly in dermatological practice to treat a variety of inflammatory conditions. Katz lists 13 dapsone responsive conditions including dermatitis herpetiformis. Dermatological reports have suggested the drug may have an effect on a proportion of patients with cicatrical and bullous pemphigoid but there is little information about its effect on ocular disease. We describe the value of dapsone in the treatment of the acute inflammatory features of ocular pemphigoid.

Patients and methods
We studied five consecutive patients between 1984–1990 who had ocular cicatrical pemphigoid in the acute inflammatory phase. None had a history of other causes of cicatrical conjunctivitis such as chronic infection, chemical trauma, or Stevens-Johnson syndrome.

Whether or not there was a history of skin lesions all patients were examined by a dermatologist.

The first two patients were commenced on dapsone 150 mg/day but both developed haemolysis and one became cyanosed. Subsequent patients were therefore given a starting dose of 100 mg/day in divided doses and the dose was reduced to the minimum required to maintain a clinical response. Where possible treatment was discontinued but if the condition relapsed the drug was re-introduced at the previous maintenance dose.

While taking the drug each patient’s blood was examined regularly for evidence of haemolysis or anaemia.

 Conjunctival and skin biopsies and serum samples for immunological assay were taken from each patient while they were without treatment and the disease was active and when the condition was in remission during treatment. Conjunctival biopsies were taken by a snip of upper bulbar conjunctiva elevated with forceps under topical anaesthesia with amethocaine 1% eye drops. Skin snip biopsy was taken from normal skin on the volar surface of the forearm after subcutaneous injection of 1% lignocaine with adrenaline. The specimens were frozen in liquid nitrogen and direct immunofluorescence staining performed with fluorescein-labelled antisera to human IgG, IgA, IgM, and C3.

Indirect studies were performed for circulating antibodies to conjunctival epithelium and its basement membrane zone.

Figure 1  Early symblepharon in the lower fornix (case 4). This feature was often so mild as to be overlooked on initial examination.
Results

The mean age of the three male and two female patients was 60 years (range 40–72 years). Three of the five cases presented with undiagnosed chronic conjunctivitis resistant to treatment. The diagnosis was eventually made clinically when previously overlooked subconjunctival fibrosis and symblepharon were identified (Fig 1). Selective involvement of the medial or lateral canthus was not present. In the other two patients cicatricial changes were obvious on presentation (Fig 2) allowing more rapid diagnosis.

Though there was cicatrisation in all cases the main presenting problem was chronic conjunctival inflammation with discomfort and pain. Figure 3 shows the inflamed conjunctiva of one patient and Figure 4 the same eye in remission on therapy. While both eyes were involved in every case there was often marked asymmetry. On stopping the drug the latent period before recurrence of the disease varied between patients and for individual patients on different occasions ranging from 1 week to 8 months.

Patient 1 had required treatment for 20 years for primary open angle glaucoma; formerly with topical adrenaline and pilocarpine latterly topical metipiranolol and oral dichlorphenamide. Topical glaucoma therapy was stopped when pemphigoid was diagnosed but the dichlorphenamide was continued.

The acute inflammatory element of ocular pemphigoid responded to the drug in all cases with a clinical response noted between 1–4 weeks after starting dapsone (Table 1). The response time varied for different patients but was consistent for each patient on every occasion the drug was recommenced. Some patients had initially received antibiotic and steroid drops but these were discontinued when the inflammation first responded to dapsone and could not account for the improvement in the patients’ conjunctival appearance. Although the conjunctival inflammation was controlled by dapsone one case needed supplementary systemic steroid when severe corneal and scleral involvement occurred.

Toxic reactions to dapsone occurred at doses of 100 mg/day or more. There was one case of mild jaundice and one of cyanosis and haemolysis. Both patients were able to continue effective long term therapy at reduced dose.

Dermatological examination identified only one patient with a skin disorder and this was described as psoriasisform dermatitis after skin biopsy and is inconsistent with cicatrical pemphigoid. Two patients had oral signs suggestive of pemphigoid.

The immunofluorescent assay results are shown in Table 2 and categorised according to whether the patient was taking dapsone or not. Conjunctival biopsy did not stimulate ocular inflammation or progression of conjunctival fibrosis. No consistent pattern of immunological results can be detected.

Discussion

The cicatrical features of ocular pemphigoid are well recognised but the acute manifestations of the disease are not. Mondino reports swollen
mounds of conjunctiva during episodes of acute disease activity which interrupt and exacerbate the conjunctival shrinkage. Wright included conjunctival ulceration with fluorescein staining in the clinical diagnostic criteria for ocular cicatricial pemphigoid. The patients reported in our paper illustrate the acute inflammatory features of conjunctival induration and vascular dilatation with chronic ocular irritation. It is in these aspects that responded to dapsone therapy.

Although the condition is rare10 the diagnosis of ocular pemphigoid should be considered in any patient presenting with undiagnosed conjunctival inflammation. There is a condition with cicatricial conjunctivitis known as linear IgA disease which is responsive to dapsone.13 None of our patients had any extraocular lesions consistent with linear IgA disease or dermatitis herpetiformis.

Case 1 may represent pseudo-pemphigoid initiated by 20 years of topical antiglaucoma therapy.1516 However the persistence of acute conjunctival inflammation after discontinuing topical medication makes the diagnosis less likely. The association of pemphigoid and topical therapy for glaucoma has been described by Tauber et al15 who found that 26% of 111 cases of ocular cicatrical pemphigoid had a history of medical therapy for glaucoma for an average of 11 years. Nearly all had this treatment before the onset of pemphigoid suggesting that glaucoma medication may be a causative factor. Whether this is a separate 'pseudo-pemphigoid' condition or merely pemphigoid in which the usually idiopathic trigger factor has been identified is known they are histologically and immunologically indistinguishable.1617 Both seem to respond equally to dapsone.

Cicatrical pemphigoid remains a clinical diagnosis. Immunological tests may confirm the diagnosis when positive but do not exclude the diagnosis when negative. Only two patients in our study showed the diagnostic finding of linear immunoglobulin deposition at the conjunctival basement membrane (cases 2 and 4) and this disappeared when the patients were taking dapsone. One other (case 3) had circulating IgG and IgA to conjunctival basement membrane but paradoxically the serum immunoglobulins were only present when the patient was taking dapsone and disappeared when treatment was discontinued. Several patients had antibodies to conjunctival epithelium on direct and indirect testing but this has been shown to be a non-specific finding in several chronic conjunctival conditions.1819 Immunological findings in pemphigoid are known to be inconsistent20 and do not correlate with extent or activity of disease.21

From our study it seems that an initial dose of 100 mg/day should be effective with little risk of side effects. A maintenance dose of between 50 mg/day and 50 mg on alternate days seems adequate. In practice once control was achieved patients were able to adjust their own maintenance dose according to the severity of their symptoms and at all times they remained under medical supervision. Rogers et al recommend an initial low dose and a gradual increase over a 2 week period to the therapeutic level but they found the ocular features of pemphigoid less responsive to dapsone than mucosal ulceration elsewhere. We observed remissions of variable duration but all patients eventually relapsed and the fact that the relapsed patients were repeatedly brought into remission again within 2 weeks of recommencing the drug was the most convincing clinical evidence that dapsone is effective in this condition. Side effects have been reported with dapsone principally haemolysis and methaemoglobinemia. Doses of more than 50 mg/day invariably produce a degree of haemolysis which seldom lowers the haemoglobin level by more than 1 g but does elevate serum bilirubin. Unless patients have cardiopulmonary problems or pre-existing anaemia the drop in haemoglobin is usually well tolerated. Methaemoglobinemia is not a major problem and even in patients taking 200 mg of dapsone per day the level does not usually exceed 2% of the total haemoglobin and is often less than 5%.1 This may give the patient a grey cyanosed appearance but is otherwise asymptomatic. Dapsone is relatively non-toxic and particularly in an elderly population seems safer to use than other possible means of treatment such as systemic steroids or immunosuppressants.2223

The mode of action of dapsone is unknown despite considerable investigation. The drug appears to act by inhibiting the migration of neutrophil polymorphonuclear leucocytes. Whether this is achieved by inhibiting lysosomal enzyme activity, interfering with the leucocytes' cytotoxic system24 or preventing the cell responding to chemotactic stimuli25 remains to be established.

---


---

Table 1  Patient details and response to dapsone showing minimum maintenance dose and length of asymptomatic remissions without treatment. All patients still require therapy

<table>
<thead>
<tr>
<th>Age</th>
<th>Sex</th>
<th>Response time (weeks)</th>
<th>Maintenance dose of dapsone (mg/day)</th>
<th>Duration of remission off dapsone (weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>2</td>
<td>50</td>
<td>6-32</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>2-4</td>
<td>50</td>
<td>4</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>2</td>
<td>100</td>
<td>10-16</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>3</td>
<td>50</td>
<td>1-16</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>1</td>
<td>50</td>
<td>1</td>
</tr>
</tbody>
</table>

---

Table 2  Summary of immunofluorescent results. Tests were carried out both on and off treatment in every case. Although positive on at least one occasion in each case the pattern did not correlate with either disease activity or treatment

<table>
<thead>
<tr>
<th>On dapsone</th>
<th>Off dapsone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient</td>
<td>Clinical state</td>
</tr>
<tr>
<td>1</td>
<td>Inactive</td>
</tr>
<tr>
<td>2</td>
<td>Inactive</td>
</tr>
<tr>
<td>3</td>
<td>Inactive</td>
</tr>
<tr>
<td>4</td>
<td>Inactive</td>
</tr>
<tr>
<td>5</td>
<td>Inactive</td>
</tr>
</tbody>
</table>

L = linear; E = intraepithelial; C = to conjunctiva; BM = to basement membrane; ND = not done.
Dapsone therapy for the acute inflammatory phase of ocular pemphigoid

FIFTY YEARS AGO

Syphilis

War brings many horrors in its train; not the least of these is an increase in syphilis.

I indicated at the outset that syphilis had shown a definite annual decline in the years preceding the present war. I regret that the number of new acute cases is now beginning to show an alarming increase; this will not be seen in ophthalmology until later on, but unless the acute cases are properly treated it will surely occur, it may be not for ten or fifteen years, when the congenital syphilitic children reach puberty or the half treated cases arrive with lesions of the central nervous system.

Dapsone therapy for the acute inflammatory phase of ocular pemphigoid.

A. I. Fern, J. L. Jay, H. Young and R. MacKie

Br J Ophthalmol 1992 76: 332-335
doi: 10.1136/bjo.76.6.332

Updated information and services can be found at:
http://bjo.bmj.com/content/76/6/332

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/